Barclays’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.4M | Buy |
946,900
+915,400
| +2,906% | +$73.2M | 0.01% | 667 |
|
|
2025
Q4 | $3M | Hold |
31,500
| – | – | ﹤0.01% | 2640 |
|
|
2025
Q3 | $3.08M | Hold |
31,500
| – | – | ﹤0.01% | 2541 |
|
|
2025
Q2 | $3.38M | Sell |
31,500
-47,500
| -60% | -$4.81M | ﹤0.01% | 2427 |
|
|
2025
Q1 | $7.97M | Sell |
79,000
-99,700
| -56% | -$10M | ﹤0.01% | 1568 |
|
|
2024
Q4 | $16M | Hold |
178,700
| – | – | ﹤0.01% | 1257 |
|
|
2024
Q3 | $15M | Sell |
178,700
-802,400
| -82% | -$63.3M | ﹤0.01% | 1225 |
|
|
2024
Q2 | $75.6M | Buy |
+981,100
| New | +$71.8M | 0.02% | 486 |
|
|
2022
Q2 | – | Sell |
-204,200
| Closed | -$9.04M | – | 5033 |
|
|
2022
Q1 | $9.04M | Buy |
204,200
+108,300
| +113% | +$4.69M | 0.01% | 946 |
|
|
2021
Q4 | $4.07M | Buy |
+95,900
| New | +$4.03M | ﹤0.01% | 1860 |
|
|
2021
Q1 | – | Sell |
-10,300
| Closed | -$370K | – | 4711 |
|
|
2020
Q4 | $370K | Hold |
10,300
| – | – | ﹤0.01% | 3426 |
|
|
2020
Q3 | $394K | Hold |
10,300
| – | – | ﹤0.01% | 3407 |
|
|
2020
Q2 | $362K | Sell |
10,300
-111,100
| -92% | -$4M | ﹤0.01% | 3600 |
|
|
2020
Q1 | $3.96M | Buy |
121,400
+50,900
| +72% | +$1.99M | ﹤0.01% | 1668 |
|
|
2019
Q4 | $3.19M | Buy |
70,500
+8,900
| +14% | +$372K | ﹤0.01% | 2494 |
|
|
2019
Q3 | $2.51M | Sell |
61,600
-65,600
| -52% | -$2.78M | ﹤0.01% | 2589 |
|
|
2019
Q2 | $5.47M | Buy |
127,200
+74,500
| +141% | +$2.87M | ﹤0.01% | 1790 |
|
|
2019
Q1 | $2.02M | Buy |
52,700
+24,800
| +89% | +$947K | ﹤0.01% | 2564 |
|
|
2018
Q4 | $986K | Sell |
27,900
-1,600
| -5% | -$58K | ﹤0.01% | 3116 |
|
|
2018
Q3 | $1.14M | Sell |
29,500
-456,200
| -94% | -$15.9M | ﹤0.01% | 3503 |
|
|
2018
Q2 | $15.9M | Buy |
485,700
+87,400
| +22% | +$2.64M | 0.01% | 917 |
|
|
2018
Q1 | $10.9M | Buy |
398,300
+386,600
| +3,304% | +$10.5M | 0.01% | 1140 |
|
|
2017
Q4 | $290K | Sell |
11,700
-9,900
| -46% | -$273K | ﹤0.01% | 4369 |
|
|
2017
Q3 | $630K | Sell |
21,600
-229,000
| -91% | -$6.32M | ﹤0.01% | 3399 |
|
|
2017
Q2 | $6.95M | Buy |
250,600
+236,700
| +1,703% | +$6.28M | 0.01% | 1224 |
|
|
2017
Q1 | $346K | Sell |
13,900
-63,200
| -82% | -$1.54M | ﹤0.01% | 3771 |
|
|
2016
Q4 | $1.67M | Sell |
77,100
-131,700
| -63% | -$2.87M | ﹤0.01% | 2277 |
|
|
2016
Q3 | $4.97M | Buy |
208,800
+17,000
| +9% | +$406K | 0.01% | 1299 |
|
|
2016
Q2 | $4.48M | Buy |
191,800
+82,400
| +75% | +$1.78M | 0.01% | 1395 |
|
|
2016
Q1 | $1.97M | Buy |
109,400
+74,500
| +213% | +$1.31M | ﹤0.01% | 1933 |
|
|
2015
Q4 | $628K | Buy |
34,900
+15,100
| +76% | +$271K | ﹤0.01% | 3020 |
|
|
2015
Q3 | $317K | Sell |
19,800
-6,700
| -25% | -$115K | ﹤0.01% | 3757 |
|
|
2015
Q2 | $451K | Sell |
26,500
-14,500
| -35% | -$259K | ﹤0.01% | 3555 |
|
|
2015
Q1 | $697K | Buy |
41,000
+5,300
| +15% | +$83.8K | ﹤0.01% | 3291 |
|
|
2014
Q4 | $464K | Sell |
35,700
-130,000
| -78% | -$1.66M | ﹤0.01% | 3923 |
|
|
2014
Q3 | $1.82M | Buy |
165,700
+108,800
| +191% | +$1.37M | ﹤0.01% | 2749 |
|
|
2014
Q2 | $683K | Sell |
56,900
-159,200
| -74% | -$2.07M | ﹤0.01% | 3687 |
|
|
2014
Q1 | $2.81M | Buy |
216,100
+152,700
| +241% | +$2M | ﹤0.01% | 2216 |
|
|
2013
Q4 | $761K | Sell |
63,400
-12,800
| -17% | -$151K | ﹤0.01% | 3683 |
|
|
2013
Q3 | $838K | Sell |
76,200
-11,300
| -13% | -$122K | ﹤0.01% | 3548 |
|
|
2013
Q2 | $811K | Buy |
+87,500
| New | +$742K | ﹤0.01% | 3656 |
|
Other funds holding BSX
VCM
VPM
Barclays's BSX Position: Q1 2026 in Review
Barclays increased its Boston Scientific (BSX) stake by 15% in Q1 2026, buying an estimated $53.1M and bringing the position to 5,024,157 shares worth $315M. The position accounts for 0.08% of the portfolio, ranked #193.
Barclays first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $558M in Q1 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Barclays held 5,024,157 shares of Boston Scientific worth $315M as of Q1 2026.
- Barclays bought 663,465 Boston Scientific shares in Q1 2026, an estimated $53.1M.
- Boston Scientific made up 0.08% of Barclays's portfolio in Q1 2026, its #193 holding.
- Barclays first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
- Barclays's Boston Scientific position peaked at $558M in Q1 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.